Immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.
Phase 2
- Conditions
- Pediatric soft tissue malignancy and neuroblastoma
- Registration Number
- JPRN-UMIN000013251
- Lead Sponsor
- Osaka university graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
1) active infectious diseases 2)Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 3)Other severe problems unsuitable for this study active infectious diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year progress free survival rate
- Secondary Outcome Measures
Name Time Method overall survival, safety, 4 -year progress free survival rate